The anti-EGFR monoclonal antibodies cetuximab (ErbituxTM, Bristol Myers Squibb and Merck KGaA) and panitumumab (VectibixTM, Amgen) are approved for the treatment of metastatic colorectal cancer (mCRC) [29, 30]. Here, EGFR is linked to metastatic colorectal cancer.